Janux Therapeutics, a biopharmaceutical company based in San Diego, is considering selling the business and other options, people with knowledge of the matter told Bloomberg.
A financial adviser is working with the company to deliberate future plans, including a potential sale to other drugmakers, according to the April 10 report. Janux develops tumor-activated T cell therapies for cancer. Its shares quadrupled this year and has a market value of $2.3 billion, according to Bloomberg.
Janux was founded in 2017 and has four products in early research stages, according to its website.